Za one koji ne vjeruju da farmaceutske kuće žive od, a ne za bolesnike, malo sam si dala truda pa stavila na jedno mjesto podatke o fin.rezultatima dotičnih kompanija. Podaci su sa njihovih stranica, ne sa nikakvih foruma. (za prijevod onima koji ne razumiju, molim upotrijebiti Google prevoditelj).
Avonex (interferon beta 1a) za intramuskularnu primjenu, 1 × tjedno
Tysabri (natalizumab)
BIOGEN IDEC Biogen Idec is among the world's leading global biotechnology companies. We are a Fortune 500 company with more than
$4 billion in revenue. Patients in more than 90 countries benefit from our products.
That's one perspective on Biogen Idec, though it is not the only one.
To our patients, we are the trusted source of vital therapies for multiple sclerosis, such as AVONEX® and TYSABRI®. We also discovered and co-market RITUXAN®, the world's most prescribed treatment for non-Hodgkin's lymphoma and an effective treatment for rheumatoid arthritis. Our patients count on us not only for medications, but also for a variety of support programs that help them deal with the rigors of living with serious illness.
Rebif (interferon beta 1a) za supkutanu primjenu, 3 × tjedno
Merck Serono
With comprehensive skills in all areas from research and development to manufacturing, marketing and sales, the division offers its world-class products in over 150 countries worldwide. Our strategically positioned workforce of 8,000 sales and marketing employees ensures commercial coverage in the U.S. and Canada, Latin America, Europe, Asia-Pacific and Japan.
The division has leading brands serving patients in its therapeutic areas of focus:
Neurodegenerative diseases – Rebif®, Novantrone®
Merck Serono is a market leader in the treatment of Multiple Sclerosis (MS) with Rebif®, approved for the treatment of relapsing-remitting MS in over 80 countries worldwide. In the United States, we market Novantrone® for worsening forms of MS.
Each year, Merck Serono dedicates over 20% of total revenues or around EUR 1 billion to research and develop new treatments in our therapeutic areas of focus.
Global sales of Rebif® for the treatment of relapsing forms of multiple sclerosis rose 13% to € 381 million in the 3rd quarter. The increase was especially strong in the United States due to higher prices and increased volumebThe new RebiSmart™ electronic injection device, which makes the self-administration of Rebif® easier and is designed for improving patient compliance with treatment, is now available in Canada and six European countries.
Sales of the targeted cancer treatment Erbitux® jumped by 33% in the 3rd quarter to € 177 million. Erbitux® is now approved in 77 countries to treat colorectal cancer and in 72 countries to treat head and neck cancer.
Tema: Razne vesti (Pročitano 265839 puta)